Neoadjuvant therapy impact in early pancreatic cancer: "bioborderline" vs. "non-bioborderline".
Alvaro Gregorio Morales TaboadaPablo Lozano LomincharFernández-Martínez MaríaPilar García AlfonsoAndrés Muñoz MartinJosé Manuel AsencioPublished in: Annals of hepato-biliary-pancreatic surgery (2022)
A neoadjuvant strategy seemed to improve local control and the survival of patients with early pancreatic cancer, both those with elevated CA19-9 and normal marker levels.